Celsion's liver-cancer therapy may extend survival

Celsion's (CLSN) ThermoDox treatment for hepatocellular carcinoma (HCC), the most common type of liver cancer, may significantly improve overall survival rates in patients.

The conclusion comes from the post-hoc analysis of the Phase III HEAT Study of ThermoDox; a year ago, the company said that ThermoDox failed in its primary goal of progression-free survival.

Celsion believes that the latest data supports the continued Phase III testing of ThermoDox.

Shares are +4.4%. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs